Gentian Diagnostics Receives Notice of Allowance for NT-proBNP Assay Patent in Japan

19 Mar 2025 08:47 CET

Moss, 19 March 2025

Gentian Diagnostics, a fast growing developer and manufacturer of diagnostic
tests, is pleased to announce that the Japanese Patent Office has issued a
notice of allowance for the company’s patent application related to its
NT-proBNP diagnostic assay. This upcoming patent grant further strengthens
Gentian’s intellectual property portfolio and enhances its position in the heart
failure diagnostics market.

Japan is the third-largest in vitro diagnostics (IVD) market for laboratory
diagnostics related to heart failure testing, following the United States and
China. Securing intellectual property protection in this key market provides
Gentian with significant commercial opportunities and reinforces the company’s
strategic position in heart failure diagnostics.

The patent protects Gentian’s innovative approach to NT-proBNP measurement using
turbidimetric immunoassay technology. This development builds upon Gentian’s
existing patents, including its granted U.S. patent, reinforcing the company’s
competitive advantage and providing strong protection against potential market
entrants.

“This patent represents a significant milestone for Gentian and further
validates our commitment to advancing high-precision diagnostic solutions,” said
Torsten Knüttel, VP R&D of Gentian Diagnostics. “Securing this protection in
Japan, one of the world’s leading healthcare markets, strengthens our global
market position and provides new opportunities for commercialization.”

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian’s expertise and focus lies within
immunoassays, specifically infection, inflammation, kidney disease and heart
failure. By converting existing and clinically relevant biomarkers to the most
efficient automated, high-throughput analyzers, the company contributes to
saving costs and protecting life. Gentian is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.

IR Contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

More information:
Access the news on Oslo Bors NewsWeb site